Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

level.

Keyphrases